WallStreetZenWallStreetZen

NASDAQ: REGN
Regeneron Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Regeneron Pharmaceuticals earnings were $4.5B for the trailing 12 months ending Jun 30, 2025, with 3.6% growth year over year. The latest REGN earnings report on Jun 30, 2025 announced Q2 2025 earnings of $1.4B, up 72.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, REGN reported annual earnings of $4.4B, with 11.6% growth.

REGN past earnings growth

How has REGN's earnings growth performed historically?

Company
3.57%
Industry
31.8%
Market
29.92%
REGN's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
REGN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
REGN's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

REGN earnings history

Current Revenue
$14.2B
Current Earnings
$4.5B
Current Profit Margin
31.4%
REGN's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

REGN Return on Equity

Current Company
15.1%
Current Industry
-7.9%
Current Market
27.2%
REGN's Return on Equity (15.1%)... subscribe to Premium to read more.
High Return on Equity Performance

REGN undefined

Current Company
11.8%
Current Industry
1.4%
REGN is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when REGN announces earnings.

REGN undefined

Current Company
14.21%
Current Industry
8.8%
REGN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

REGN vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
REGN$5.42B$4.46B+8.90%$41.76
ALNY-$192.50M-$319.09MN/A-$2.47
ARGX$811.30M$1.51BN/A$25.02
ONC$98.95M-$177.64MN/A-$0.13
BNTX-$27.18M-$405.65MN/A-$1.68
View Top Biotech Stocks

Regeneron Pharmaceuticals Earnings Reports & History FAQ

What were Regeneron Pharmaceuticals's earnings last quarter?

On REGN's earnings call on Invalid Date, Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q2 2025 earnings per share (EPS) of $13.24, up 0.08% year over year. Total REGN earnings for the quarter were $1.39 billion. In the same quarter last year, Regeneron Pharmaceuticals's earnings per share (EPS) was $13.25.

If you're new to stock investing, here's how to buy Regeneron Pharmaceuticals stock.

Is Regeneron Pharmaceuticals profitable or losing money?

As of the last Regeneron Pharmaceuticals earnings report, Regeneron Pharmaceuticals is currently profitable. Regeneron Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $4.46 billion, a 3.17% increase year over year.

What was REGN's earnings growth in the past year?

As of Regeneron Pharmaceuticals's earnings date in Invalid Date, Regeneron Pharmaceuticals's earnings has grown 3.57% year over year. This is 28.23 percentage points lower than the US Biotechnology industry earnings growth rate of 31.8%. REGN earnings in the past year totalled $4.46 billion.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.